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Abstract. Malignant mesothelioma (MM) is an aggressive 
and highly chemoresistant tumour. Although cisplatin is used 
in frontline therapy of this disease treatment remains palliative 
at best. The biochemical pathways activated by cisplatin and 
the mechanisms of resistance in mesothelioma cells are poorly 
understood. Overexpression of inhibitor of apoptosis proteins 
(IAPs) has been described in clinical mesothelioma tumours 
and proposed as therapeutic targets. In this study, we exam-
ined cisplatin-induced cell death pathways and IAPs in three 
mesothelioma-derived cell lines. Cisplatin induced cell death 
in mesothelioma cell lines was characterised by biochemical 
mechanisms classically associated with apoptosis including: 
mitochondrial depolarisation, phosphatidylserine transloca-
tion and caspase activation. Surprisingly mRNA expression of 
IAPs in mesothelioma was not upregulated relative to primary 
mesothelial cells except for survivin which was higher in the 
most resistant cell line. In contrast, protein expression of both 
XIAP and survivin was upregulated in all mesothelioma cells, 
consistent with post-translational regulation. Knockdown of 
either XIAP or survivin by RNAi did not affect the sensitivity 
to cisplatin in any of the cell lines. Survivin RNAi did, however, 
inhibit proliferation in the highest expressing cell line, ONE58. 
The pan-caspase inhibitor z-VAD and the more selective caspase 
3/7 inhibitor z-DEVD had no effect upon the sensitivity of any 
of the cell lines to cisplatin indicating that caspase-independent 
pathways predominate. The findings of the present study provide 
insights into cisplatin-induced mechanisms in mesothelioma 
cells and show that alternative pathways are operating which 
may provide new options for targeting this extremely resistant 
tumour.
Introduction
Malignant mesothelioma (MM) is a rare and aggressive tumour, 
accounting for less than 1% of all cancer deaths in the world (1). 
Although malignant mesothelioma is rare, it is a particularly 
aggressive cancer and despite the exploration of a variety of 
new therapeutic approaches, treatment remains palliative at 
best (2).
The platinum based compound cisplatin is a widely used 
chemotherapeutic agent which acts primarily via DNA damage 
and subsequent induction of apoptotic programs (3). Cisplatin 
based chemotherapy, either as a single agent or in combination, 
is commonly employed in therapy of malignant mesothelioma, 
although its efficacy is limited (2). The antineoplastic activity 
of cisplatin is rather complex and in light of the published 
reports it appears that cisplatin may activate several parallel 
pathways leading to cell cycle arrest and apoptosis depending 
on the treatment conditions, cell type or concentration (4). Due 
to this complexity and lack of cytotoxic efficiency in meso-
thelioma, our knowledge about particular molecular targets of 
cisplatin in this type of malignancy remains limited despite this 
compound being widely used in its treatment. Recent evidence 
from clinical samples has suggested that as for other malignan-
cies inhibitor of apoptosis proteins (IAPs) are upregulated in 
mesothelioma and may play a role the resistance of these cells 
to therapy (5-7).
Previous research conducted in our laboratory has chara-
cterised the mechanisms of cisplatin-induced apoptosis in 
malignant mesothelioma cell lines derived from mice (8). The 
initial aim of this study was to characterise the in vitro culture 
models of human MM, for mechanisms involved in the action 
of cisplatin (9). Thus in our study we wanted to explore in detail 
the possible proapoptotic mechanisms of cisplatin in highly 
aggressive mesothelioma cell lines while also examining the 
role of IAPs in resistance of this tumour. Various therapies are 
under development targeting IAPs and in particular XIAP and 
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survivin in a number of malignancies (10) and we wanted to 
investigate in detail the potential of such therapies in mesothe-
lioma using a panel of cell lines. We found that in these cell 
lines IAPs were not a factor in cisplatin resistance and that 
cisplatin instead targets caspase-independent pathways.
Materials and methods
Cell culture and reagents. The malignant mesothelioma cell 
lines JU77, LO68 and ONE58 were used in this study. These 
cell lines were originally derived from pleural effusions of 
different patients presenting with malignant pleural mesothe-
lioma (9). All cells were cultured and maintained in medium 
R5, which is RPMI-1640 plus 5% heat-inactivated fetal bovine 
serum (FBS), 300 mM L-glutamine, 120 µg/ml penicillin and 
100 µg/ml gentamicin (all supplied by Invitrogen, Victoria, 
Australia). All cell cultures were grown at 37˚C in a 5% CO2 
humidified atmosphere. Mesothelial cell RNA and protein 
was kindly provided by Dr Steve Mutsaers (Lung Institute of 
Western Australia).
Cell viability. An MTT assay was used to quantitate cell death/
viability following 24 h exposure to cisplatin. Cells were 
seeded into 96-well plates at a density of 20,000 cells/well. 
Following 24 h incubation, cisplatin was added at concentra-
tions from 0-100 µg/ml and the cells incubated for a further 
24 h. The assay was terminated by aspirating the media, 
100 µl of 1 mg/ml MTT (Sigma-Aldrich, NSW, Australia) 
in RPMI was added and the plates incubated for 60 min at 
37˚C. Following removal of the supernatant 100 µl of DMSO 
was added to solubilise the dye and absorbance measured 
at 595 nm with a microplate reader (Model 3550, Bio-Rad 
Laboratories, CA, USA). IC50 was defined as the concentration 
causing a 50% reduction in absorbance relative to the negative 
control. IC50 was determined by non-linear regression analysis 
using Graphpad Prism v4 (Graphpad Software, CA, USA).
Annexin-V and propidium iodide staining. Annexin-V and 
Propidium Iodide (PI) staining was performed using an 
Annexin-V-Fluos kit (Roche Diagnostics, NSW, Australia). 
Cells were seeded into 6-well plates at a density of 5x105 cells/
well. Following 24 h incubation cisplatin was added at concen-
tration 0-100 µg/ml and the cells incubated for a further 24 h. 
Cells were harvested by trypsinization, collected by centrifuga-
tion, washed once with 1 ml of PBS and stained according to 
the manufacturers' protocol and analysed using a FACS Calibur 
Flow Cytometer (BD Biosciences, NSW, Australia).
Determination of the mitochondrial transmembrane poten-
tial. ΔΨm was analysed using the cationic dye JC-1 (5, 5', 6, 
6'-tetrachloro-1, 1', 3, 3'-tetraethyl-benzimidazolcarbocyanine 
iodide) which exhibits potential-dependent accumulation 
in mitochondria by fluorescence emission shift from green 
(~525 nm) to red (~590 nm). Consequently, mitochondrial 
depolarization is indicated by a decrease in the red/green fluo-
rescence intensity ratio. Cells were seeded into black 96-well 
plates (Greiner, Germany) at a density of 10,000 cells/well in 
100 µl R5. Following 24 h incubation, cisplatin was added at 
concentrations from 0-100 µg/ml and the cells were incubated 
for a further 24 h. The media was then aspirated and 50 µl of 
staining solution added [33 µM JC-1 (Invitrogen) in serum free 
R-5], and the plates incubated for 1 h at 37˚C, 5% CO2. The 
staining solution was then removed and 200 µl of PBS with 5% 
BSA was added. After a further 5-min incubation, PBS/BSA 
was removed and 100 µl PBS was added. The plates were read 
on a Fluostar Optima plate reader (excitation filter 485 nm and 
emission filters 520 nm /595 nm) (BMG Laboratories, Victoria, 
Australia). Data are presented as the ratio of red to green. FCCP 
[carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone] 
(Sigma-Aldrich) was used as a positive control for maximal 
mitochondrial depolarisation.
Caspase activity assay. Activation of effector caspases during 
apoptosis was determined using the Caspase-3 Assay kit#2 
(Invitrogen) with a protocol modified for a direct homoge-
neous assay. Cells were seeded into black 96-well plates 
(Greiner) at a density of 20,000 cells/well in 100 µl medium. 
Following 24 h incubation, cisplatin was added at concentra-
tions from 0-100 µg/ml and the cells incubated for a further 
24 h. The assay was terminated by the addition of 100 µl of 
reagent buffer (5 µl 20X cell lysis buffer, 20 µl 5X reaction 
buffer, 0.5 µl substrate z-DEVD-R110, 0.5 µl of 1M DTT, 74 µl 
dH2O) and the fluorescent signal measured after 1 h (Fluostar 
Optima, BMG Laboratories). Appropriate blank and control 
samples were included in each run as recommended by the 
assay manufacturer. Caspase inhibitors were the pan-caspase 
inhibitor z-VAD-fmk and the caspase 3/7 inhibitor z-DEVD-
cmk (Calbiochem, Victoria, Australia).
Reverse transcription PCR (RT-PCR) and real-time RT-PCR. 
Total RNA was isolated from cultures of the cell lines using 
Ultraspec RNA reagent (Biotec, TX, USA) according to the 
manufacturer's instructions. The RNA pellet was resuspended 
in 1 mM sodium citrate buffer and samples were stored at -80˚C. 
Prior to RT-PCR, contaminating DNA was removed from the 
RNA using RQ1 DNAse (Promega, NSW, Australia). First strand 
cDNA synthesis was performed using SuperScript III First-
Strand Synthesis System with oligo dT primers (Invitrogen). 
Gene specific PCR primers were designed using the Primer 3 
software (11) and the sequences are shown in Table I. Real-time 
PCR was performed using a RotorGene real-time amplifica-
tion instrument (Corbett Research, NSW, Australia) using a 
SensiMix SYBR kit (Bioline, NSW, Australia) according to 
the manufacturers' instructions. A melt curve analysis was 
performed at end of each experiment to confirm specificity.
Gene expression data were normalised to levels of expres-
sion of reference (housekeeping) genes GAPDH and HPRT1. 
PCR primers were as follows: survivin (NM_001168) forward 
(5'-cttgaaagtggcaccagagg-3'), reverse (5'-ggaccaccgcatct 
ctacat-3'); XIAP (NM_001167) forward (5'-ggggttcagtttcaa 
gga-3'), reverse (5'-cgccttagctgctcttcagt-3'); IAP1 (NM_001165) 
forward (5'-cctggatagtctactaactgcct-3'), reverse (5'-gcttct 
tcagagagtttctgaa-3'); IAP2 (NM_001160) forward (5'-cagaat 
tggcaagagctggt-3'), reverse (5'-attcgagctgcatgtgtct-3'); HPRT1 
(NM_000194) forward (5'-tgacactggcaaaacaatgca-3'), reverse 
(5'-ggtccttttcaccagcaagct-3') and GAPDH (NM_002046) 
forward (5'-accacagtccatgccatcac-3'), reverse (5'-tccaccacc 
ctgttgctgta-3'). Real-time assays were performed on the relevant 
samples and from the reference gene data generated for each 
sample using geNorm software (v3.3) essentially as described 
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by Vandesompele et al (12). Relative expression of the target 
gene was normalised using this factor and expressed as mean ± 
standard deviation relative to a control or calibrator sample.
Immunoblot analysis. Cell monolayers were washed once with 
ice-cold saline and lysed by addition of RiPa buffer [50 mM 
Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-100, 0.5% Na 
deoxycholate, 0.1% SDS) with protease inhibitors (Roche 
Biochemicals)]. Incubated for 1 h at 4˚C with gentle agitation 
then harvested with a cell scraper and transferred to a 1.5 ml 
tube. The lysate was then centrifuged at 12,000 g for 30 min. 
at 4˚C and the supernatants recovered and stored at -80˚C. 
Protein concentrations were determined by DC protein assay 
(Bio-Rad). Proteins were resolved on 4-12% NuPAGE poly-
acrylamide gels (Invitrogen) and transferred to nitrocellulose 
membrane (Pall, Victoria, Australia) and probed with the 
following antibodies: anti-XIAP (Cell Signaling Technology, 
MA, USA), anti-survivin (BioLegend, CA, USA) and anti-actin 
(Sigma-Aldrich). After incubation with alkaline phosphatase 
conjugated secondary antibody, colour was developed using 
5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium 
reagents (Sigma-Aldrich).
Cell-based ELISA. A cell-based ELISA assay was used to 
monitor changes in protein expression in response to RNAi 
duplex transfection. Preliminary experiments were performed 
to optimise the conditions for each cell line with respect to cell 
density and antibody concentration. Following treatment in 
96-well plates, the experiment was terminated by removing the 
media and fixing the cells with ice-cold methanol for 10 min. 
Figure 1. Mechanisms of cisplatin induced cell death in mesothelioma cells. (A) In vitro sensitivity of MM cell lines to cisplatin. Cells were cultured in the presence 
of cisplatin for 24 h. Cell viability was determined by MTT assay. Data presented are the mean ± SD of five independent experiments each performed in triplicate. 
(B) Dose-dependent mitochondrial membrane depolarisation. Mitochondrial membrane potential was measured by JC-1 accumulation following cisplatin treat-
ment (lower ratio of red/green indicates loss of potential). Results are the mean ± SD of at least three independent treatments performed in triplicate. FCCP-positive 
control. (C) Phosphatidylserine (PS) translocation in response to cisplatin. PS translocation to the outer cell membrane was measured by Annexin-V binding and 
flow cytometry. Cells were treated with a range of cisplatin concentrations (0.1-100 µg/ml) for 24 h. Results shown are the mean ± SD of two independent experi-
ments performed in triplicate. (D) Loss of membrane integrity in response to cisplatin. Membrane integrity was measured by staining with the cell impermeant 
dye propidium iodide and flow cytometry. Results shown are the mean ± SD of two independent experiments performed in triplicate.
Table I. The sequences used.
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The methanol was aspirated and the cells were rinsed 3 times 
for 5 min each with 200 µl per well of 0.1% Triton X-100 in 
PBS. The cells were incubated for 5 min with 100 µl of 3% 
H2O2 (to block endogenous peroxidase activity), washed twice 
with 0.5% Tween-20 in PBS (wash buffer) and then blocked 
with 5% FBS in PBS for 30 min. Cells were washed 3 times, 
incubated overnight with primary antibody (as for immunoblot) 
and following three washes incubated at room temperature for 
1 h with HRP conjugated secondary antibody. Detection was 
performed for 1 h with ABTS (2,2'-azinodiethyl-benzthiazoline 
sulfonate) substrate (Sigma-Aldrich), stopped with 1% SDS and 
absorbance measured at 405 nm. Appropriate background and 
antibody controls were included in each assay.
RNAi-mediated gene silencing. The siRNA duplexes were 
Stealth Select 3 RNAi Sets for human XIAP and survivin 
(Invitrogen) and the optimal duplex as determined empirically 
for each cell line was used for the experiments presented here. 
The negative control duplexes were the appropriate (based 
upon GC content) Stealth siRNA negative controls (Invitrogen). 
Transfection of RNAi duplexes was performed using 
Lipofectamine (Invitrogen, Australia) essentially according to 
the manufacturers recommendation with concentration deter-
mined empirically.
Results
Mechanisms of cisplatin induced cell death in mesothelioma 
cells. In order to examine the mechanisms of cisplatin effect 
upon mesothelioma we initially evaluated the in vitro sensitivity 
of three mesothelioma cell lines, LO68, ONE58 and JU77 
to 24 h exposure to cisplatin (0.1-100 µg/ml) by MTT assay. 
Results were determined by constructing dose-response curves 
(Fig. 1A) and the IC50 calculated by further non-linear regres-
sion analysis of the data. The results showed that JU77 (IC50 
of 1.14±0.21 µg/ml) and LO68 (IC50 of 1.2±0.45 µg/ml) were 
the most cisplatin sensitive cell lines when compared to ONE58 
(IC50 of 3.08±0.83 µg/ml).
Given the importance of mitochondria in cell death 
regulation and apoptotic signalling we examined mitochon-
drial functional integrity in cisplatin treated mesothelioma 
cells. Mitochondrial disruption and the loss of mitochondrial 
membrane potential (MMP) was assayed using the fluorescent 
mitochondrial potential sensor (JC-1). We found that all three 
mesothelioma cell lines exhibited dose-dependent loss of 
MMP following cisplatin treatment (Fig. 1B). Interestingly, at 
100 µg/ml in both JU77 and ONE58 cisplatin inhibited the 
function of mitochondria to the same extent as the positive 
control FCCP (a protonophore that dissipates the H+ gradient 
across the inner membrane of mitochondria) whereas a lesser 
effect was seen in LO68 cells.
In order to further explore the specific mechanisms associ-
ated with cisplatin-induced cell death in this tumour cell type, 
the biochemical changes in the cell membrane associated with 
apoptosis were measured (Fig. 1C and D). All three cell lines 
demonstrated increased Annexin-V binding indicative of phos-
phatidylserine translocation in response to cisplatin treatment, 
which was most pronounced in JU77 cells (Fig. 1C). When PI 
staining showing loss of membrane integrity was determined, 
JU77 cells also showed response at a lower dose than LO68 or 
ONE58 cells (Fig. 1D). These results were consistent with cell 
viability data showing JU77 as the most sensitive (Fig. 1A).
Caspase activation and IAP expression in MM cells. We char-
acterised time- and dose-dependent patterns of cisplatin induced 
caspase-3/7 activation in these cell lines. Cultures of JU77, LO68 
and ONE58 were treated with cisplatin and dose-related changes 
in caspase 3/7 activity were assayed at 0, 3, 6 and 24 h. All MM 
cell lines demonstrated an increase in caspase 3/7 activation in 
response to cisplatin (Fig. 2), although no effect was seen at 3 h 
(not shown). Caspase 3/7 activation occurs at a later time with 
lower doses of cisplatin (Fig. 2B), whereas with higher doses 
of cisplatin, caspase 3/7 activation occurs earlier (Fig. 2A). In 
JU77 increases in caspase 3/7 activity was demonstrated at low 
concentrations of cisplatin (1-10 µg/ml) after 24 h of exposure 
(Fig. 2A). Interestingly, the most pronounced upregulation in 
caspase activity was seen in LO68 cells. In contrast, overall 
caspase 3/7 activation in ONE58 cells was only seen at 10 µg/
ml at 24 h and in no other sample.
We next investigated the expression of IAPs in these cells 
since reports have indicated overexpression of some of these 
molecules in MM (5,6) with implications for apoptosis resis-
tance. Using conventional PCR we found that IAP-1, IAP-2, 
Figure 2. Dose- and time-dependent caspase activation by cisplatin. Caspase 
activity was measured (A) 6 h and (B) 24 h following cisplatin treatment. Data 
are presented as fold increase in fluorescence as measured relative to untreated 
cultures. Data are the mean ± SD of two independent treatments performed in 
triplicate. Ctrl cells treated with caspase 3/7 inhibitor ac-DEVD-cho. 
INTERNATIONAL JOURNAL OF ONCOLOGY  42:  444-452,  2013448
XIAP, and survivin mRNAs were expressed in all MM cell lines 
(data not shown) and we went on to examine differential expres-
sion of these genes in MM cells and primary mesothelial cell 
cultures (Fig. 3). We found that gene expression of both IAP1 
and survivin were upregulated in ONE58 cells (Fig. 3A and D) 
which may account for the lack of caspase activation in these 
cells but that otherwise there was no clear pattern of expression 
difference between the MM cell lines and mesothelial cultures. 
Since some authors (13,14) have reported that cisplatin can 
downregulate IAP expression in tumour cells we also examined 
the mRNA levels of IAPs by real-time PCR following 3, 6 and 
24 h of treatment with 10 µg/ml cisplatin but we did not see 
any significant changes in IAP expression in MM cells (data 
not shown). To further investigate IAP expression in these cells 
we performed immunoblotting studies of XIAP and survivin 
protein expression (Fig. 4) which demonstrated higher levels of 
both these proteins in the MM tumour cell lines than in primary 
cells. Given the results of the mRNA analysis of these genes 
(Fig. 3B and D) this suggests a level of translational regulation 
of these molecules.
Silencing of XIAP and survivin in mesothelioma cells. Since 
immunoblotting studies indicated differential expression of both 
XIAP and survivin protein in mesothelioma cell lines (Fig. 4) 
we further investigated the role of these proteins in resistance 
to cisplatin using RNAi mediated knockdown. Previously, in 
our laboratory (unpublished data) we observed that mRNA 
knockdown by RNAi may not correlate with protein. Therefore, 
we employed cell based ELISA assays for XIAP and survivin 
to optimise for RNAi mediated knockdown at the protein level.
In all three cell lines we were able to establish conditions 
which achieved optimal knockdown to at least 40% of XIAP 
Figure 3. Basal gene expression of (A) IAP1 (B) XIAP (C) IAP2 and (D) survivin in mesothelioma and primary mesothelial cells (MC). Total RNA isolated from 
cells was analysed by 2-step real-time RT-PCR using gene specific primers. Basal gene expression is expressed as mRNA levels relative to mesothelial culture C 
(MC-C) following normalisation by reference gene expression. Results are means ± SD for three cultures. 
Figure 4. IAPs are differentially expressed at the protein level in mesothe-
lioma cells. Proteins extracted from mesothelioma and three different primary 
mesothelial cell cultures (MC) were analysed by immunoblotting with rele-
vant antibodies. Results are representative of three different determinations.
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Figure 5. Effect of IAP knockdown by RNAi upon in vitro sensitivity to cisplatin. (A) JU77 XIAP (B) LO68 XIAP (C) ONE58 XIAP (E) JU77 survivin (F) LO68 
survivin (G) ONE58 survivin. Cells were transfected with optimal RNAi duplexes and then incubated for 48 h for optimal knockdown and cultured in the presence 
of cisplatin (5 and 10 µg/ml) for 24 h. Cell viability was determined by MTT assay. Each bar represents the mean ± SD from three independent experiments. *There 
was a significant decrease in cell viability in ONE58 cells following survivin knockdown p<0.05 (Fisher's t-test). Extent of IAP protein knockdown by RNAi: (D) 
XIAP (H) survivin. Cells were transfected as above and after 48 h assayed by cell ELISA for relative protein expression. Each bar represents the mean ± SD from 
two independent experiments. 
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(Fig. 5D) 48-72 h after transfection. Experiments in JU77, LO68 
and ONE58 showed that knockdown of XIAP had little effect 
upon the sensitivity of these cell lines to cisplatin (Fig. 5A-C). 
Subsequently a similar series of experiments was conducted 
using RNAi mediated knockdown of survivin. It proved more 
difficult in these cells to knock down survivin at the protein 
level (Fig. 5H) than XIAP, although the effect in ONE58 cells 
(the highest expressing) was comparable. Similarly the sensi-
tivity of JU77 and LO68 cells (Fig. 5E and F) to cisplatin was 
not affected by survivin knockdown. In ONE58 cells survivin 
protein downregulation had a significant effect upon baseline 
cell viability (Fig. 5G) although this was independent of 
cisplatin treatment.
Caspase independence of cisplatin-induced cell death in 
mesothelioma cells. Given the lack of effect of knockdown of 
XIAP and survivin upon drug cytotoxicity we hypothesised 
that caspase activation may be unnecessary for the effect of 
cisplatin in these cells. Therefore, we investigated the effect 
of both the pan-caspase inhibitor z-VAD-fmk and the caspase 
3/7 inhibitor z-DEVD-cmk upon these cells. Both of these 
inhibitors effectively blocked caspase 3/7 activation by cisplatin 
(Fig. 6D). Neither broad nor the more narrow spectrum caspase 
inhibition significantly influenced cisplatin induced cytotoxicity 
in mesothelioma cells (Fig. 6A-C). These results suggest that in 
these cell lines caspase activation is not essential for cell death 
due to cisplatin and most likely caspase-independent pathways 
predominate.
Discussion
In the present study, we have characterised the cisplatin chemo-
sensitivity of malignant mesothelioma cell lines (JU77, LO68 
and ONE58), and investigated in detail the mechanisms of cell 
death induced by this chemotherapeutic which is commonly 
employed in the clinical treatment of MM. Conventionally the 
best understood pathway of cisplatin toxicity is activation of 
DNA damage signalling pathways which trigger mitochondrial 
apoptosis (15). Our initial experiments established the cytotoxic 
effect and relative sensitivity of 3 mesothelioma cells lines to 
cisplatin. Examination of biochemical mechanisms induced 
by cisplatin demonstrated changes generally associated with 
apoptotic cell death including mitochondrial depolarisation 
and characteristic membrane changes. The active involvement 
of caspases is considered one of the hallmarks of cytotoxic 
drug-induced apoptosis. We focussed upon the executioner 
caspase 3/7 and found activation in both JU77 and LO68 but 
much less in ONE58 (the most resistant cell line).
We next investigated basal expression of IAPs in these cells 
given the purported role of these molecules in resistance to drug 
induced cytotoxicity (10). Survivin mRNA was upregulated 
in ONE58 consistent with the low caspase activation in these 
cells. However, apart from this we did not see the difference 
in XIAP and survivin expression that was expected from the 
literature (5-7). While upregulation of basal IAPs have been 
reported in numerous studies few have examined changes in 
IAP gene expression in response to cisplatin treatment. We 
did not find regulation of IAP gene expression in response to 
cisplatin treatment in the present study. Results of other studies 
have provided conflicting evidence for the regulation of IAPs 
Figure 6. Effect of caspase inhibition upon in vitro sensitivity to cisplatin. (A) 
JU77 (B) LO68 (C) ONE58. Cells were cultured in the presence of cisplatin 
(0-20 µg/ml) for 24 h following exposure to caspase inhibitors. Cell viability 
was determined by MTT assay. Results are mean ± SD of three independent 
treatments performed in triplicate. (D) Caspase inhibitors effectively block cis-
platin induced caspase activation. Cells were incubated with a range of caspase 
inhibitors and exposed to cisplatin (0-20 µg/ml) for 24 h. Caspase activity was 
measured after 24 h and expressed as fold increase relative to untreated cells. 
Results are the mean ± SD of at least two independent treatments performed in 
triplicate.
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in response to chemotherapeutic drugs including cisplatin 
(13,14,16). Our results are consistent with this being a cell 
type- and drug-dependent mechanism which does not operate 
downstream of cisplatin in mesothelioma cells.
Surprisingly, immunoblotting revealed differential expres-
sion of both XIAP and survivin at the protein level which was 
not seen in mRNA, with the exception of survivin in ONE58 
cells. While many studies have focussed upon differences in 
mRNA levels of these proteins there is also evidence for signifi-
cant regulation of both at the protein level (10). Both XIAP 
(17) and survivin (18) have been shown as regulated through 
mechanisms controlling the proteasome degradation pathway. 
In addition there is evidence for other posttranslational mecha-
nisms functioning to regulate these proteins (reviewed in refs. 
19 and 20).
Our results for protein expression were consistent with the 
few studies which have investigated IAP molecules in clinical 
samples of mesothelioma (6,7). However, a role for these proteins 
in resistance to cisplatin was not borne out by our subsequent 
experiments. The XIAP protein knockdown achieved by us was 
at a level consistent with similar studies in other cell types which 
showed effects upon viability and drug sensitization (21,22). 
Our data indicate that inhibition of caspase activation by XIAP 
was not likely to be important in the resistance of mesothelioma 
cell lines to cisplatin.
The frequent overexpression of survivin in cancer is well 
recognised and often associated with resistance to therapy 
poor prognosis and an aggressive progression (10), therapies 
targeting this molecule are in various stages of development 
(23). We achieved a 40-60% knockdown of this protein, 
however, as with XIAP, there was no effect upon cisplatin 
sensitivity. Most studies have merely assessed cell viability 
directly following survivin knockdown rather than in conjunc-
tion with drug treatment and we did observe a significant effect 
upon cell viability in ONE58 cells. Targeting survivin by RNAi 
in other cell types combined with drugs has shown conflicting 
results with sensitization (24) or no effect (25). Several previous 
studies have examined the functional effects of inhibition of 
survivin in mesothelioma cell lines finding enhanced caspase 
activation (7,26) and apoptotic morphology (7) in response to 
cisplatin. In the present study we used a panel of three distinct 
mesothelioma cell lines and assessed viability along with 
other apoptotic mechanisms, caspase activation was observed 
(unpublished data) but this did not affect cell viability.
In addition to more recently described mechanisms, inhibi-
tion of caspase activation either directly by XIAP or indirectly 
by survivin remains an important function of these proteins 
(10). We speculated that the absence of effect by RNAi in 
our experiments may relate to caspase activation. Our finding 
that cisplatin induced cell death in mesothelioma cells did not 
require caspase activation confirmed this. To our knowledge 
this is the first time that caspase-independent pathways have 
been identified as prominent in mesothelioma cells response to 
chemotherapy.
Classical apoptosis pathways involving caspase activation 
are the most widely described cisplatin induced mechanisms 
(15) although there is a growing body of evidence for caspase 
independent pathways (27-30). These pathways are increas-
ingly of interest because they represent a level of redundancy in 
cell death signalling which might be therapeutically exploited 
in tumours which are inherently resistant to apoptosis (31). 
Notable in the present study was the commonality of the find-
ings regarding caspase independence in all three cell lines under 
investigation. Current studies in our laboratory are directed at 
elucidating the alternate pathways operating in these cells.
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